Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clonazepam + tianeptine
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of clonazepam, a benzodiazepine with anxiolytic and anticonvulsant properties, and tianeptine, an atypical tricyclic antidepressant with mu-opioid receptor agonist activity. This combination may be used for treating comorbid depression and anxiety disorders. The combination increases the risk of sedation and requires careful monitoring.
02
Targets
DOR (Opioid Receptor Delta 1)GABRR (GABA-A receptor subunit rho)GluR (Glutamate receptors)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on clonazepam + tianeptine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clonazepam + tianeptine.